Displaying drugs 10976 - 11000 of 14389 in total
PF-00217830
PF-00217830 has been used in trials studying the treatment of Schizophrenia.
Investigational
Thiopropazate
Experimental
Telaglenastat
Telaglenastat is under investigation in clinical trial NCT02071862 (Study of the Glutaminase Inhibitor CB-839 in Solid Tumors).
Investigational
ATG002
ATG002 is a completely new approach to treating chronic wounds such as diabetic foot ulcers, which is based upon stimulation of angiogenesis in the wound bed to help drive the wound-healing process. Unlike protein-derived growth factors, ATG002 is a small molecule that, applied topically, effectively penetrates through the wound and...
Investigational
Matched Description: … factors, ATG002 is a small molecule that, applied topically, effectively penetrates through the wound and …
Oxypurinol
Oxypurinol, an inhibitor of xanthine oxidase, is a metabolite of allopurinol.
Investigational
CRx-119
CRx-119 is a novel synergistic combination drug candidate discovered using the CombinatoRx combination High Throughput Screening (cHTS(TM)) technology with potential therapeutic use in a broad range of immuno-inflammatory conditions. CRx-119 is a combination of a low dose of the steroid prednisolone, 3mg, and amoxapine.
Investigational
Matched Description: … CRx-119 is a combination of a low dose of the steroid prednisolone, 3mg, and amoxapine. …
SR 140333
SR 140333 is tachykinin antagonist which has potential to treat diarrhoea due to food allergy or inflammatory bowel disease.
Investigational
DP-b99
DP-b99 is a newly developed lipophilic, cell permeable derivative of BAPTA (1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid), that is under development as a neuroprotectant for the potential treatment of stroke, head trauma and neurological damage associated with coronary artery bypass graft.
Investigational
Matched Description: … , that is under development as a neuroprotectant for the potential treatment of stroke, head trauma and …
MDX-1303
MDX-1303 is a fully human antibody against the inhalation anthrax, the most lethal form of illness in humans caused by the Bacillus anthracis bacterium, and targets a protein component of these lethal toxins known as the anthrax protective antigen.
Investigational
Matched Description: … inhalation anthrax, the most lethal form of illness in humans caused by the Bacillus anthracis bacterium, and …
GlycoPEG-GCSF
GlycoPEG-GCSF is a long-acting GlycoPEGylated granulocyte colony stimulating factor for the treatment of chemotherapy-induced neutropenia.
Investigational
CAM-2029
CAM2029 is a new ready-to-use, long-acting octreotide formulation being developed for the long-term treatment of acromegaly, carcinoid syndrome and vasoactive intestinal peptide (VIP)-producing tumours. CAM2029 was found to provide long-acting release of octreotide resulting in a statistically significant suppression of a clinical biomarker insulin-like growth factor 1 (IGF-1) over the...
Investigational
Matched Description: … octreotide formulation being developed for the long-term treatment of acromegaly, carcinoid syndrome and …
Aminoimidazole carboxamide
Investigational
Zosuquidar
Zosuquidar is a compound of antineoplastic drug candidates currently under development. It is now in "Phase 3" of clinical tests in the United States. Its action mechanism consists of the inhibition of P-glycoproteins; other drugs with this mechanism include tariquidar and laniquidar.
Investigational
Matched Description: … mechanism consists of the inhibition of P-glycoproteins; other drugs with this mechanism include tariquidar and …
Torcetrapib
Torcetrapib (CP-529414, Pfizer) was developed to treat hypercholesterolemia but its development was halted in 2006 when phase III studies showed excessive mortality in the treatment group receiving a combination of atorvastatin and the study drug.
Investigational
Matched Description: … III studies showed excessive mortality in the treatment group receiving a combination of atorvastatin and …
Elsiglutide
Investigational
Annamycin
Investigational
Semaxanib
Investigational
Vicriviroc
Vicriviroc, also known as SCH 417690 and SCH-D, is currently in clinical trials for the management of HIV-1. This pyrimidine based drug inhibits the interaction of HIV-1 with CCR5, preventing viral entry into cells. This drug was developed by Schering-Plough.
Investigational
Matched Description: … Vicriviroc, also known as SCH 417690 and SCH-D, is currently in clinical trials for the management of …
Perflubron
Perflubron (Oxygent) is being developed as an intravascular oxygen carrier designed to augment oxygen delivery in surgical patients.
Investigational
Atiprimod
Investigational
Mx-dnG1
Investigational
Displaying drugs 10976 - 11000 of 14389 in total